earnings
confidence high
sentiment negative
materiality 0.85
Teladoc Q1 net loss $6.67B on $6.6B goodwill impairment; cuts 2022 guidance
Teladoc Health, Inc.
2022-Q1 EPS reported
-$41.58
revenue$565,350,000
- Q1 revenue $565.4M (+25% YoY); net loss $6.67B due to $6.6B non-cash goodwill impairment ($41.11/sh).
- Adjusted EBITDA $54.5M (-4% YoY); net loss per share $41.58 vs. $1.31 a year ago.
- FY 2022 guidance revised: revenue $2.4-2.5B, adj. EBITDA $240-265M, net loss per share ($43.50)-($43.00).
- D2C mental health hit by higher ad costs with lower yield; chronic condition sales cycles elongated.
- Primary360 and stepped-care chronic programs launched on multiple new clients in Q1.